Aprea Therapeutics reports Q2 2024 net loss of $3.5M; Phase 1 trial initiated for APR-1051

Aprea Therapeutics, Inc.

2024-Q2 EPS reported -$1.24

Cash $28.7M as of June 30, 2024, up from $21.6M at Dec 31, 2023; runway extended into Q4 2025.
Net loss $3.5M ($0.58 per share) vs $3.3M ($0.87) in Q2 2023; operating loss $3.8M.
Enrollment commenced in Phase 1 ACESOT-1051 trial of APR-1051 (WEE1 inhibitor); no myelosuppression in first cohort.
ABOYA-119 Phase 1/2a trial of ATRN-119 (ATR inhibitor) continues; first five dose cohorts completed; Phase 1 readout expected 1H 2025.
Appointed Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer effective May 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.